Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis, with a median overall survival of approximately five months [1]. The risk for CNS disease has been estimated to be about 5% overall [2], but it is significantly higher in ce...
The CNS international prognostic index (CNS‐IPI) is a clinical CNS relapse risk score that has not specifically been validated in elderly patients. The value of CNS prophylaxis in patients aged ≥70years remains uncertain. Data on 690 consecutively R‐CHOP‐treated DLBCL patients aged ≥70years ...
Prophylaxis with high‐dose methotrexate significantly reduces CNS dissemination in patients with diffuse large B‐cell lymphoma (DLBCL) and high‐risk CNS‐IPI scoreIt is widely demonstrated that the PI3K-AKT-mTOR signalling is critical in normal myeloid and lymphoid development and function. Thus, ...
CNS disease in patients with DLBCL has a high mortality rate, prompting some clinicians to use prophylaxis against CNS disease in these patients. However, practice patterns and outcomes associated with CNS prophylaxis have not been well characterized since the adoption of rituximab as a standard compo...
However, practice patterns and outcomes associated with CNS prophylaxis have not been well characterized since the adoption of rituximab as a standard component of DLBCL therapy. To investigate, Dr. Abel and colleagues took advantage of the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outco...
We conducted a phase 2 trial in 139 patients aged 18 to 64 years who had primary DLBCL with an age-adjusted International Prognostic Index (aaIPI) score of 2 to 3 or site-specific risk factors for CNS recurrence. The goal was to assess whether a dose-dense immunochemotherapy with early ...
e19036 Background: Double hit lymphoma (DHL) is a high-grade lymphoma with a propensity to involve the central nervous system (CNS) compared to the typically less aggressive diffuse large B cell lymphoma (DLBCL). Guidelines recommend considering cerebrospinal fluid (CSF) evaluation and prophylaxis ...
CD37, whose expression is related to improved patient survival in peripheral DLBCL, while its loss is a risk factor for therapy resistance with rituximab [41], was also reduced in the hyperexpanded clones (Fig. 3H, Additional file 10: Table S8). Enrichment analysis showed that BCR, RAC1, ...
(CD52,IGHD,MS4A1) were reduced in the hyperexpanded clones compared to all other clones. CD37, whose expression is related to improved patient survival in peripheral DLBCL, while its loss is a risk factor for therapy resistance with rituximab [41], was also reduced in the hyperexpanded ...
The CNS international prognostic index (CNS‐IPI) is a clinical CNS relapse risk score that has not specifically been validated in elderly patients. The value of CNS prophylaxis in patients aged ≥70?years remains uncertain. Data on 690 consecutively R‐CHOP‐treated DLBCL patients aged ≥70?